Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update

Clinical Pharmacokinetics
Jessica C Song, C Michael White

Abstract

The angiotensin converting enzyme (ACE) inhibitors are widely used in the management of essential hypertension, stable chronic heart failure, myocardial infarction (MI) and diabetic nephropathy. There is an increasing number of new agents to add to the nine ACE inhibitors (benazepril, cilazapril, delapril, fosinopril, lisinopril, pentopril, perindopril, quinapril and ramipril) reviewed in this journal in 1990. The pharmacokinetic properties of five newer ACE inhibitors (trandolapril, moexipril, spirapril, temocapril and imidapril) are reviewed in this update. All of these new agents are characterised by having a carboxyl functional groups and requiring hepatic activation to form pharmacologically active metabolites. They achieve peak plasma concentrations at similar times (t(max)) to those of established agents. Three of these agents (trandolapril, moexipril and imidapril) require dosage reductions in patients with renal impairment. Dosage reductions of moexipril and temocapril are recommended for elderly patients, and dosages of moexipril should be lower in patients who are hepatically impaired. Moexipril should be taken 1 hour before meals, whereas other ACE inhibitors can be taken without regard to meals. The pharmacokinetic...Continue Reading

References

Jan 1, 1992·Pharmacology & Therapeutics·G D Johnston
May 1, 1991·Hypertension·R J AndersonR Zusman
Jun 1, 1991·Journal of Clinical Pharmacology·B F JohnsonJ Flemming
Aug 1, 1991·The New England Journal of Medicine·UNKNOWN SOLVD InvestigatorsJay N Cohn
Sep 1, 1990·Clinical Pharmacokinetics·J G Kelly, K O'Malley
Feb 1, 1990·American Journal of Hypertension·M Rose, F G McMahon
Jan 1, 1989·British Journal of Clinical Pharmacology·P E WilliamsC Durnin
May 1, 1989·American Journal of Hypertension·A Salvetti, F Arzilli
Oct 1, 1989·British Journal of Clinical Pharmacology·H J GomezE P MacCarthy
Apr 1, 1989·Angiology·E L KinneyJ W Caldwell
Sep 1, 1987·British Journal of Clinical Pharmacology·A RakhitR Williams
Feb 16, 1988·European Journal of Pharmacology·C ChevillardM Worcel
Oct 1, 1988·Clinical Pharmacology and Therapeutics·K R LeesJ L Reid
Jan 1, 1988·British Journal of Clinical Pharmacology·S M SinghviM Frantz
Sep 1, 1985·Clinical Pharmacokinetics·S H Kubo, R J Cody
Apr 24, 1987·The American Journal of Cardiology·B H MeyerD Schmidt
Mar 1, 1988·Journal of Clinical Pharmacology·G M KochakM E Hurley
Jul 1, 1988·Clinical Pharmacology and Therapeutics·A RakhitG M Feldman
Jan 1, 1987·Clinical Pharmacology and Therapeutics·H ShionoiriY Kaneko
Sep 1, 1982·British Journal of Clinical Pharmacology·E H UlmJ L Schelling
Sep 1, 1994·Journal of Cardiovascular Pharmacology·E DelacrétazH R Brunner
Mar 27, 1993·Lancet·J Lob-levyt
Mar 1, 1994·British Journal of Clinical Pharmacology·M J VandenburgS Brugier
Jan 1, 1993·European Journal of Clinical Pharmacology·A Van HeckenP J De Schepper

❮ Previous
Next ❯

Citations

Nov 8, 2006·European Journal of Clinical Pharmacology·G A ChristieW S Waring
Feb 25, 2005·International Clinical Psychopharmacology·Jonathan M MeyerIn-Lin Tuan
May 3, 2005·Journal of Medical Genetics·M R AbdollahiI N M Day
Jan 20, 2006·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Eiichi GeshiTakashi Katagiri
Jan 20, 2004·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Amos Pines, Enrique Z Fisman
Feb 25, 2014·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Paolo DentiNeil H Davies
Jul 6, 2014·Drug Discovery Today·Katarzyna RegulskaMarek Murias
Dec 10, 2003·Expert Opinion on Emerging Drugs·J A Whitworth
Apr 20, 2005·Clinical and Experimental Hypertension : CHE·Masami Ohmori, Akio Fujimura
May 25, 2007·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·B V KaranamS Vincent
Dec 17, 2004·Journal of Veterinary Pharmacology and Therapeutics·P L Toutain, H P Lefèbvre
Jul 22, 2008·Journal of Veterinary Pharmacology and Therapeutics·P O DesmoulinsL J I Horspool
Aug 3, 2004·Journal of Clinical Pharmacology·Steven G Chrysant, George S Chrysant
Mar 20, 2004·Expert Review of Cardiovascular Therapy·Steven G Chrysant, George S Chrysant
Mar 8, 2019·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Takashin NakayamaSatoru Komatsumoto
Apr 23, 2020·Clinical Pharmacology and Therapeutics·Krishna Sriram, Paul A Insel
Jul 18, 2020·Chemical Biology & Drug Design·Ambili Unni PGirinath G Pillai
Oct 31, 2003·Expert Opinion on Drug Safety·Renke Maas, Rainer H Böger
Sep 29, 2020·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Maureen CzickRobert Shapter
Feb 13, 2016·Pharmacogenetics and Genomics·Jonathan C SanfordWolfgang Sadee
Jan 17, 2020·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Julio Caballero
Feb 3, 2012·Clinical Pharmacology and Therapeutics·D GnjidicD G Le Couteur
May 21, 2021·Journal of Agricultural and Food Chemistry·Md Yousof AliImtiaz Khan
Oct 27, 2021·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Joseph M CollinsDanxin Wang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antiarrhythmic Agents: Mechanisms of Action

Understanding the mechanism of action of antiarrhythmic agents is essential in developing new medications as treatment of cardiac arrhythmias is currently limited by the reduced availability of safe and effective drugs. Discover the latest research on Antiarrhythmic Agents: Mechanism of Action here.